Back to search results

A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma

Abroad (travel likely)RecruitingPHASE2

Conditions

Monoclonal Gammopathy of Undetermined Significance (MGUS) · Smoldering Multiple Myeloma (SMM)

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Johns Hopkins Hospital, Baltimore, Maryland, United States

  • Dana-Farber Cancer Institute, Boston, Massachusetts, United States

  • University of Michigan Health, Ann Arbor, Michigan, United States

  • NYU Langone Health Perlmutter Cancer Center, New York, New York, United States

  • Stony Brook University Hospital, Stony Brook, New York, United States

  • Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States

  • University of Washington, Seattle, Washington, United States

  • Algemeen Ziekenhuis (AZ) Klina, Brasschaat, Antwerpen, Belgium

  • AZ St.-Elisabeth Herentals vzw, Herentals, Antwerp, Belgium

  • AZ Sint Maarten Algemeen Ziekenhuis Emmaus, Mechelen, Flanders, Belgium

  • Algemeen Ziekenhuis St Jan Brugge Oostende Av, Bruges, West-Vlaanderen, Belgium

  • Algemeen Ziekenhuis AZ Delta, Roeselare, West-Vlaanderen, Belgium

  • Ziekenhuis Netwerk Antwerpen Cadix, Hematology, Antwerp, Belgium

  • Centre Hospitalier Universitaire De Poitiers, Poitiers, New Aquitaine, France

  • Institut Curie, Paris, Île-de-France Region, France

  • Galway University Hospital, Galway, Connacht, Ireland

  • Cork University Hospital, Cork, Ireland

  • Mater Misericordiae University Hospital, Dublin, Ireland

  • Istituto Romagnolo per lo Studio Dei Tumori Dino Amadori, Meldola, Forli-Cesena, Italy

  • IRCCS Ospedale Policlinico San Martino, Genoa, Genova, Italy

  • San Paolo Hospital, Milan, Lombardy, Italy

  • Azienda Ospedaliero Universitaria (AOU) SS. Antonio e Biagio e Cesare Arrigo, Alessandria, Piedmont, Italy

  • UOC Ematologia e Terapia Cellulare - PO Mazzoni AST Ascoli Piceno, Ascoli Piceno, Italy

  • Universita degli Studi di Pavia - Fondazione IRCCS Policlini, Pavia, Italy

  • Ospedale Santa Maria delle Croci, Ravenna, Italy

  • Wojewodzki Szpital Zespolony - Ludwik Rydygier Provincial Hospital, Torun, Kuyavian-Pomeranian Voivodeship, Poland

  • Specjalistyczny Szpital im A. Sokolowskiego w Walbrzychu, Wałbrzych, Lower Silesian Voivodeship, Poland

  • Pratia MCM Krakow, Krakow, Malopolska, Poland

  • University Clinical Center / Medical University of Gdansk, Gdansk, Pomeranian Voivodeship, Poland

  • Wojewodzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im. Mikolaja Kopernika w Lodzi (Copernicus Memorial Hospital), Lodz, Poland

  • Swietokrzyskie Centrum Onkologii, Kielce, Świętokrzyskie Voivodeship, Poland

  • Hospital Universitario Virgen de las Nieves, Granada, Andalusia, Spain

  • Hospital Universitari Mutua Terrassa, Terrassa, Barcelona, Spain

  • Hospital Clinico Universitario Virgen De La Arrixaca, El Palmar, Murcia, Spain

  • Hospital de Cabuenes, Gijón, Principality of Asturias, Spain

  • Hospital Sant Pau, Barcelona, Spain

  • Institut Catala dOncologia (ICO Hospitalet), Barcelona, Spain

  • Universitaru Hospital La Princesa, Madrid, Spain

  • Hospital General Universitario Morales Meseguer, Murcia, Spain

Study leads

  • Clinical Trial Management

    Study Director

    Regeneron Pharmaceuticals

View source on ClinicalTrials.gov(opens in a new tab)